Related Experiment Video

Updated: Oct 23, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.4K

Prostaglandin Reductase 1 as a Potential Therapeutic Target for Cancer Therapy

Xing Wang1,2, Guobing Yin1, Wei Zhang2

  • 1Department of Breast and Thyroid Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Frontiers in Pharmacology
|August 23, 2021
PubMed

Insights

Prostaglandin Reductase 1 (PTGR1) is a key enzyme in cancer metabolism. Targeting PTGR1 offers a promising new strategy for developing novel cancer therapeutics and treatments.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Altered tumor metabolism is a critical hallmark of cancer.
  • Targeting cancer metabolism presents a viable therapeutic strategy.
  • Prostaglandin Reductase 1 (PTGR1) regulates eicosanoid metabolism, influencing cancer progression.

Purpose of the Study:

  • To review recent advancements in understanding PTGR1 structure and function.
  • To highlight the significant roles of PTGR1 in various cancers.
  • To discuss potential PTGR1 inhibitors and future research directions.

Main Methods:

  • Literature review of PTGR1 research.
  • Analysis of PTGR1's role in cancer pathways.
  • Identification and summary of PTGR1 inhibitors.

Main Results:

  • PTGR1 is a rate-limiting enzyme in arachidonic acid metabolism.
  • PTGR1 deactivates prostaglandins and leukotriene B4, impacting cancer.
  • Evidence supports PTGR1 as a novel therapeutic target in oncology.

Conclusions:

  • PTGR1's function and structure are increasingly understood.
  • PTGR1 plays a crucial role in cancer development and progression.
  • Further research into PTGR1 inhibitors holds therapeutic potential for cancer treatment.
Keywords:
PTGR1cancer therapeuticseicosanoid pathwaysinhibitortumor metabolism

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.4K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

8.9K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
291
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
718
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K